Literature DB >> 15711909

GH receptor antagonist: mechanism of action and clinical utility.

Sowmya K Surya1, Ariel L Barkan.   

Abstract

This review focuses on the development of GH receptor antagonist as a novel agent for treatment of acromegaly, its mechanism of action and potential areas of use. A brief overview of acromegaly, its diagnosis and existing medical, surgical and radiotherapy options of treatment is necessary to justify the addition of yet another therapeutic modality to the already vast therapeutic armamentarium.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15711909     DOI： 10.1007/s11154-005-5219-x

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN： 1389-9155            Impact factor:   6.514


  66 in total

1.  Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.

Authors:  P J Trainer; W M Drake; L A Perry; N F Taylor; G M Besser; J P Monson
Journal:  J Clin Endocrinol Metab       Date:  2001-07       Impact factor: 5.958

Review 2.  Acromegaly.

Authors:  S Melmed
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

3.  Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice.

Authors:  Y Segev; D Landau; R Rasch; A Flyvbjerg; M Phillip
Journal:  J Am Soc Nephrol       Date:  1999-11       Impact factor: 10.121

4.  Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.

Authors:  A Colao; P Marzullo; D Ferone; V Marinò; R Pivonello; C Di Somma; A Di Sarno; A Giaccio; G Lombardi
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

5.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

Authors:  A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

6.  Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.

Authors:  Pamela U Freda; Abu T Nuruzzaman; Carlos M Reyes; Robert E Sundeen; Kalmon D Post
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

7.  Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2.

Authors:  K C Leung; N Doyle; M Ballesteros; K Sjogren; C K W Watts; T H Low; G M Leong; R J M Ross; K K Y Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

8.  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

Authors:  B Swearingen; F G Barker; L Katznelson; B M Biller; S Grinspoon; A Klibanski; N Moayeri; P M Black; N T Zervas
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

9.  Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.

Authors:  A L Barkan; R P Kelch; N J Hopwood; I Z Beitins
Journal:  J Clin Endocrinol Metab       Date:  1988-01       Impact factor: 5.958

10.  Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.

Authors:  P U Freda; K D Post; J S Powell; S L Wardlaw
Journal:  J Clin Endocrinol Metab       Date:  1998-11       Impact factor: 5.958
View more
  1 in total

1.  Differential Effects of Hormones on Cellular Metabolism in Keratoconus In Vitro.

Authors:  Tina B McKay; Jesper Hjortdal; Henrik Sejersen; Dimitrios Karamichos
Journal:  Sci Rep       Date:  2017-02-17       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.